Lilly Asia Ventures achieved an exit in a Hong Kong offering in which the oncology therapy developer floated at the top of its range.

Legend Star and CMB International are among the participants in the cancer drug developer’s latest round, which was led by Tsing Song Capital.

Tencent Investment was among the participants in late-stage round for the online medical information and social networking service.

Lilly Asia Ventures has put more funding into Transcenta to help sustain the antibody drug developer's clinical-stage pipeline.

The SFC-backed vaccine developer has wrapped up its series B-2 round after holding an initial close in early 2019.

AG Capital and Zenrin DataCom were among the backers that helped the mental health assessment software provider close an $11.8m round.

The Novartis-backed retinal disease drug developer has secured $46.9m of series B capital from investors including Johnson & Johnson Innovation – JJDC.

U-M's retinal disease drug developer has secured $46.9m of series B capital from investors including Mints.

The Novartis, Nan Fung, iCarbonX, Otsuka and Quest Diagnostics-backed proteomics technology developer has closed the second tranche of the round.

Tencent led a series A2 round for the cell analysis technology developer that included Lilly Asia Ventures and Softbank China Venture Capital.